RSS Feed Print
GV1001: another possible treatment for Alzheimer's disesae
Lane Simonian
Posted: Saturday, December 14, 2019 9:13 PM
Joined: 12/12/2011
Posts: 5107

This is the first time that I have seen this one, but the results and mechanism seem promising.

GemVax announced phase II results of GV1001 for Alzheimer's disease treatment at CTAD 2019

Suggests potential as a new drug for treating Alzheimer's disease

At the CTAD presentation, GemVax said the phase II study of its experimental drug called 'GV1001'conducted in moderate to severe Alzheimer's disease, met its primary endpoint, as measured by Severe Impairment Battery, or SIB.

The SIB score of the control group treated with donepezil only decreased by 7.23, while that of the experimental group treated with GV1001 high dose in combination with donepezil decreased by 0.12. The study clearly demonstrated the beneficial effects of treating Alzheimer's with GV1001.

Dr. Michael Weiner, an Alzheimer's expert from the University of California San Francisco who was one of the chairs for the session, said, "It is quite amazing results," and mentioned the possibility of GV1001 as a disease modifying drug.

Meanwhile, other researchers and the Alzheimer's experts at the CTAD shared that it is remarkable that GV1001 is effective in moderate to severe Alzheimer's disease while recent Alzheimer's drug clinical trials ended in failure.  

GemVax said it shared mechanism of actions of GV1001 in treating Alzheimer's such as anti-neuroinflammatory and mitochondrial damage protection effects with Alzheimer's experts at the conference and potential collaboration opportunities for upcoming clinical trial in the U.S. were also discussed.

And mechanism:

Neural stem cells injured by oxidative stress can be rejuvenated by GV1001, a novel peptide, through scavenging free radicals and enhancing survival signals

GV1001 is a novel 16-amino-acid peptide.

GV1001 was reported to be able to prevent the toxicity of amyloid beta.

Oxidative stress induces death of neural stem cells.

In this study, GV1001 effectively protects and rejuvenates NSCs from oxidative stress.

The action mechanisms of GV1001 are associated with anti-oxidant effects and via increasing survival signals and decreasing death signals.

There are several trials now where antioxidant compounds have greatly slowed the progression of Alzheimer's disease.

Posted: Thursday, December 19, 2019 6:52 PM
Joined: 2/17/2019
Posts: 380

Wow, this sounds like they are on the right track.